Loading...
Loading...
NEW YORK, NY · CIK 0001263508
Portfolio Value
$15.18B
Positions
99
New
9
Increased
13
Decreased
22
Sold Out
31
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $15.18B across 99 positions in their Q3 2018 SEC 13F filing (period ending 2018-09-30). The top 10 positions account for 84.7% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | SGENEURSeattle Genetics, Inc. | $3.94B | 25.93% | - |
| 2 | INCYIncyte Corporation | $2.37B | 15.59% | +0.0% |
| 3 | ONCBeiGene, Ltd. | $2.06B | 13.57% | - |
| 4 | ALXNAlexion Pharmaceuticals, Inc. | $1.19B | 7.83% | - |
| 5 | GHDXGenomic Health, Inc. | $968.40M | 6.38% | +0.0% |
| 6 | BMRNBioMarin Pharmaceutical Inc. | $735.33M | 4.84% | - |
| 7 | ACADACADIA Pharmaceuticals Inc. | $590.40M | 3.89% | +4.4% |
| 8 | Amarin Corporation plc | $554.31M | 3.65% | +50.3% |
| 9 | MDGLMadrigal Pharmaceuticals, Inc. | $250.38M | 1.65% | - |
| 10 | ASNDUSDAscendis Pharma A/S | $201.06M | 1.32% | - |
| Stock | Value | Shares |
|---|---|---|
| PRNBPrincipia Biopharma Inc. | $52.24M | 1,787,807 |
| NVAXNovavax, Inc. | $8.87M | 4,718,318 |
| VKTXViking Therapeutics, Inc. | $7.40M | 425,000 |
| ARWRArrowhead Pharmaceuticals, Inc. | $5.89M | 307,496 |
| YMABUSDY-mAbs Therapeutics, Inc. | $3.98M | 150,000 |
| CRNXCrinetics Pharmaceuticals, Inc. | $3.76M | 131,250 |
| AQSTAquestive Therapeutics, Inc. | $1.74M | 99,600 |
| AQSTAquestive Therapeutics, Inc. | $1.74M | 99,600 |
| CNSTConstellation Pharmaceuticals, Inc. | $897.00K | 133,333 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.